Charles River Laboratories International, Inc. (CRL) Market Cap & Valuation Ratios
Charles River Laboratories International, Inc. (CRL) has a market cap of $16.5B and a price-to-sales ratio of 4.1, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CRLCharles River Laboratories International, Inc.Follow CRL — free
—
Price chart with a free account
- Market cap
- 16.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
diagnostics & research · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| CRL | 16 | — | 4.7 | 48.7 | 2.2% | -0.7% | 2% | 1% |
| ILMN | 41 | 50.3 | 9.2 | 36.0 | 2.3% | +5% | 20% | 19% |
| MTD | 33 | 37.6 | 8.6 | 28.4 | 2.6% | +7% | 28% | 49% |
| LH | 27 | 27.2 | 2.3 | 14.8 | 4.3% | +6% | 10% | 9% |
| DGX | 27 | 24.1 | 2.6 | 13.6 | 5.2% | +9% | 15% | 11% |
| GH | 23 | — | 19.6 | — | -1.1% | +43% | -40% | -231% |
| MEDP | 19 | 37.2 | 6.3 | 28.4 | 3.6% | +20% | 21% | — |
| RVTY | 18 | 76.0 | 6.8 | 25.8 | 3.2% | +4% | 12% | 3% |
| ICLR | 14 | — | 2.0 | 25.1 | 6.2% | +2% | 4% | 2% |
| QGEN | 11 | 26.0 | 5.5 | 17.4 | 4.1% | +3% | 22% | 9% |
| TWST | 8.8 | — | 20.0 | — | -1.1% | +19% | -34% | -42% |
| Median of these 10 | 37.2 | 6.6 | 25.5 | 3.4% | +7% | 13% | 9% |
; EV/Sales 4.7 vs. 6.6.
Growth vs. price
each dot a company · hover or tap for valuesCRL and GH and ICLR and TWST have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
Charles River Laboratories International, Inc. — questions
- What is Charles River Laboratories International, Inc.'s market cap?
- $16.5B.
- What is Charles River Laboratories International, Inc.'s price-to-sales ratio?
- 4.1.
Every figure on this page comes from Charles River Laboratories International, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.